AI Vendor Risk in Biotech Extends the Validated System Boundary

A scientist selects twelve assay deviations, sends their narratives to a vendor model, and pastes the response into an investigation record. The prompt and completion now sit inside the process used to create a regulated electronic record. That is the mechanism behind ai vendor risk biotech. If the record is required under an FDA predicate rule, the vendor route can extend the system boundary that validation, access control and audit-trail procedures have to cover.

I want to focus the vendor assessment on that boundary, because a general security questionnaire says very little about the specific record path FDA can inspect.

TL;DR

• 21 CFR Part 11 applies to electronic records created, modified, maintained, archived, retrieved, or transmitted under FDA record requirements.
• Section 11.10 calls for validation, accurate copies, protected retrieval, authorized access, audit trails and authority checks in closed systems.
• FDA's clinical-investigation guidance addresses sponsors, investigators, IRBs, contract research organizations and other parties using electronic systems.
• Supplier evidence and request-level evidence must connect through a named system, intended use, model route, policy version and change record.

Part 11 scope follows the electronic record

21 CFR 11.1 applies to records in electronic form that are created, modified, maintained, archived, retrieved or transmitted under FDA record requirements. The predicate rule still determines which record must exist. Part 11 then sets the criteria FDA uses to treat the electronic record as trustworthy, reliable and generally equivalent to paper.

That distinction should drive the vendor inventory. A model used to rephrase an internal meeting agenda sits in a different class from a model that drafts a deviation assessment, summarizes a clinical site query, or extracts a value used in a batch decision. The latter uses can affect a regulated record and need an intended-use statement with a named owner.

The scope record should identify the source material, model output, human review step, destination system and retained evidence. The detailed logging requirements are covered in AI audit trails for biotech.

The supplier file needs Part 11 evidence

21 CFR 11.10 lists the controls for closed systems. They include validation for accuracy and consistent intended performance, accurate and complete copies suitable for FDA inspection, protected retrieval throughout retention, access limited to authorized individuals, and secure time-stamped audit trails. Authority checks must ensure that only authorized people perform the operation at hand.

A biotech vendor assessment should translate each applicable control into evidence. Validation requires a defined intended use, test results, acceptance criteria and approved deviations. Record-copy capability requires a usable export rather than screenshots assembled during an inspection. Access review needs named roles tied to each approved operation. Audit-trail review needs the events, timestamps and actor identity that the service records. Change control needs notice of model or service changes that could affect the validated state.

A SOC 2 report can support the file. It cannot answer these Part 11 questions by itself.

The model version is a change-control fact

FDA's guidance on electronic systems in clinical investigations addresses sponsors, clinical investigators, institutional review boards, contract research organizations and other interested parties. Its stated purpose is to explain how electronic systems, records and signatures can remain trustworthy and reliable in clinical investigations.

For a model service, the version and route belong in the operational record because vendor changes can alter behavior without changing the user's screen. A validation package approved against one model route says little about a later route unless the change process evaluated the difference. The supplier file should define notification duties, version pinning where available, regression tests, rollback criteria and the person authorized to accept a change.

My view is that silent model substitution should be treated as an unapproved system change in a regulated workflow. The polished chat window may look identical while the model behind it has changed. The GxP AI compliance checklist turns this principle into owner, evidence and remediation fields.

Runtime evidence completes the assessment

A supplier review captures what the vendor promises and what the biotech company approved. Runtime evidence shows which approved path people and agents used. Both records need a common system and vendor identifier.

For each authenticated HTTP model call in a regulated workflow, the evidence should capture the caller, role, application, intended use, source-data classification, destination provider, model version, policy version, outcome and timestamp. A correlation identifier should connect the call to the workflow record without placing the regulated content in every security log.

Picture the inspection request: an investigator points to a blue approval stamp on a deviation record and asks which model contributed text to it. The answer should come from a query by record identifier and date range, with the matching policy decision and vendor approval available. Reconstructing the answer from browser history and invoices is an evidence failure.

The control point belongs before transmission

Training and procedure remain necessary, but they ask the scientist to recognize every regulated context before pressing send. An inline control can use the authenticated identity, application route and request classification before the payload reaches the vendor.

The policy can deny an unapproved provider, route a regulated workflow to a pinned model, or require a model path approved for the intended use. Each result creates a record, including the denied attempt. That gives quality teams evidence that the control operated during routine work rather than only during the validation exercise.

This boundary is narrow by design. Local model execution, laboratory instrument controls and records that never traverse authenticated HTTP AI traffic remain outside it. The broader supplier programme and validation lifecycle stay with quality and system owners. The general procurement framework is described in AI vendor risk management.

DeepInspect

DeepInspect sits between authenticated biotech users or agents and HTTP-based LLM endpoints. Before transmission, it evaluates identity, application, intended route, data classification, destination model and policy. A regulated workflow can be restricted to an approved provider and model version, with unapproved routes denied.

Every decision produces a signed record with the caller, role, system identifier, classification, vendor route, model version, policy version, outcome and timestamp. Quality teams can retrieve the evidence by person, application, model or time range. DeepInspect supplies the enforcement and record for this HTTP boundary. Intended-use approval, computer-system validation and release decisions stay with the biotech company's quality organisation.

Book a demo today.